【原美源伯根】Cencora (COR) 2022年年度报告「NYSE」.pdf

1、12022Summary Annual Report02About AmerisourceBergen 03CEO letter 05Financial highlights 12Management team 14Board of Directors 15GAAP/Non-GAAP financial measures 16Corporate information 18Contents03AmerisourceBergen fosters a positive impact on the health of people and communities around the world b

2、y advancing the development and delivery of pharmaceuticals and healthcare products.We work across the pharmaceutical supply chain from assisting pharmaceutical manufacturers with steps from precommercial and clinical trial to broad market availability and patient adherence,to ensuring healthcare pr

3、oviders have efficient,reliable and secure access to the medications they need to care for their patients.AboutAmerisourceBergen4CEOletter05To our shareholdersAmerisourceBergen delivered another strong fiscal year driven by the resilience and strength of our business as our team continued to execute

4、 to advance our strategic priorities and build on our foundation to drive future growth.We leveraged our leading pharmaceutical distribution businesses,solidified our global capabilities to further enhance our customer experience,and advanced our legacy of responsible corporate stewardship.During fi

5、scal 2022,we were proud to support the ongoing global response to COVID-19 by distributing Emergency Use Authorization treatments in the U.S.and by distributing vaccines and test kits internationally.Guided by our purpose and empowered by our commercial strengths and execution,we played an important

6、 role in bolstering public health,which also presented an opportunity to enhance relationships with key stakeholders worldwide,including governments,public health agencies,providers,and pharmacies.Importantly,we continued to serve our community provider customers from pharmacies to physicians to vet